

October 15, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated October 15, 2026, titled **“Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,

For, **Zydus Lifesciences Limited**

DHAVAL
NARENDRA
SONI

Digitally signed by
DHAVAL
NARENDRA SONI
Date: 2026.10.15
11:29:37 +05'30'

Dhaval N. Soni

Company Secretary and Compliance Officer
Membership No. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka

Ahmedabad, India, 15 October, 2026

Dear Sir/Madam,

We wish to inform you that Zydus Sunshine Lifesciences (Pvt) Ltd, the proposed joint venture between Zydus Lifesciences Limited (Zydus) and Sunshine Healthcare, part of Sunshine Holdings PLC, signed an agreement with the Board of Investment of Sri Lanka on 13 October 2026 to establish a pharmaceutical manufacturing facility in the BOI zone in Horana, Sri Lanka. Both companies had announced the formation of a Joint Venture on 26 June 2026.

The project envisages a phased investment of over USD 20 million. The facility will be developed on a site of nearly four acres, with commercial operations expected to commence in 2028, subject to project timelines and relevant regulatory approvals.

In its first phase, the facility will manufacture oral solid dosage forms for the Sri Lankan market. The investment supports the Zydus' international presence and commitment to expanding access to quality medicines. Local manufacturing is expected to strengthen medicine supply chain resilience and support the availability of essential medicines in Sri Lanka.

Kindly take the above information on record.



**PRESS
RELEASE**

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878